Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Invesco Solar ETF
TAN
4
The Technology Select Sector SPDR® Fund
XLK
5
Direxion Daily Energy Bull 2X Shares ETF
ERX
CN Stock MarketDetailed Quotes
Lushang Freda Pharmaceutical (600223)
- 6.20
- 0.000.00%
Not Open May 25 15:00 CST
6.30BMarket Cap37.35P/E (TTM)
6.26High6.13Low47.60KlotVolume6.23Open6.20Prev Close29.41MTurnover0.47%Turnover Ratio33.51P/E (Static)1.02BShares9.3652wk High1.48P/B6.30BFloat Cap6.1052wk Low6.82Limit Up1.02BShs Float18.58Historical High5.58Limit Down2.10%Range %1.26Historical Low0.06Dividend TTM6.18Avg Price26.81KlotAsk0.97%Div Yield TTM100Lot Size18.93KlotBid
600223 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
600223 Orderflow
Unit: --
600223 Orderflow Trend
IntradayDayWeekMonth
No Data
Lushang Freda Pharmaceutical (600223) News
Huayuan Securities: The cosmetics sector demonstrated steady performance in Q1 2026, with high-quality domestic brands showcasing strong competitiveness.
In 2025, the year-on-year growth rate of retail sales of cosmetics goods by large-scale enterprises in China reached 5.1%, surpassing the overall consumer goods retail growth rate of 3.7%. The performance remained relatively stable.
Lushang Freda PharmaceuticalLtd's (SHSE:600223) Anemic Earnings Might Be Worse Than You Think
Furuida: Report for the First Quarter of 2026 by Lushang Furuida Pharmaceutical Co., Ltd.
Announcement by Lushang Furuida Pharmaceutical Co., Ltd. on Key Operating Data for the First Quarter of 2026
2026 First Quarter Report of Lushang Furuida Pharmaceutical Co., Ltd.
Time To Worry? Analysts Are Downgrading Their Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Outlook
Lushang Freda Pharmaceutical (600223) Stock Forum
The company may be sacrificing current earnings per share to drive growth. The modest 1.2% dividend yield is unlikely to be attracting many buyers. The company's future earnings are worth investigating, especially considering the strong total shareholder return over the past five years.
Despite the Downward Trend in Earnings at Lushang Freda PharmaceuticalLtd (SHSE:600223) the Stock Climbs 5.4%, Bringing Five-year Gains to 157% 1
Lushang Freda Pharmaceutical Co.,Ltd.'s low P/S ratio is likely due to anticipated poor revenue performance. The company's declining revenue and negative growth forecast compared to the industry's positive outlook justify its low P/S ratio.
Despite declining revenues, investors puzzlingly keep P/S from dropping, a move that appears unsustainable. The company's potential overvaluation via P/S ratio amidst poor revenue outlook suggests a premium might be paid for the stock.
Despite declining revenues, investors are questionable for keeping P/S from dropping, likely affecting the share price negatively. The company may be overvalued given the gloomy revenue outlook, suggesting a premium paid for the stock.
Investors' efforts to maintain the P/S amidst a steady revenue decline seems questionable and unsustainable. The company's potential overvaluation due to the grim revenue prospect hints at investors possibly paying more for the stock.
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)